MX344809B - Terapia adyuvante con herceptin. - Google Patents

Terapia adyuvante con herceptin.

Info

Publication number
MX344809B
MX344809B MX2013009514A MX2013009514A MX344809B MX 344809 B MX344809 B MX 344809B MX 2013009514 A MX2013009514 A MX 2013009514A MX 2013009514 A MX2013009514 A MX 2013009514A MX 344809 B MX344809 B MX 344809B
Authority
MX
Mexico
Prior art keywords
adjuvant therapy
herceptin
herceptin adjuvant
present application
breast cancer
Prior art date
Application number
MX2013009514A
Other languages
English (en)
Inventor
L Bryant John
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37450489&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344809(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX344809B publication Critical patent/MX344809B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Business, Economics & Management (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a el uso de un inmunoconjugado que comprende un anticuerpo anti-ErbB2 que se une al dominio IV de HER2 unido por trastuzumab conjugado aun maitansionoide en la preparación de un medicamento para el tratamiento de un sujeto humano que presenta cáncer positivo a HER2, en donde el tratamiento comprende administrar al sujeto humano, después de cirugía definitiva, quimioteprapia basada en antraciclina ciclofosfamida (AC), seguido por administración de una cantidad eficaz de un inmunoconjugado en combinación con una cantidad eficaz de un segundo anticuerpo anti-ErbB2, el cual es un inhibidor de dimerización de HER2.
MX2013009514A 2005-05-13 2006-04-21 Terapia adyuvante con herceptin. MX344809B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68112505P 2005-05-13 2005-05-13

Publications (1)

Publication Number Publication Date
MX344809B true MX344809B (es) 2017-01-09

Family

ID=37450489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009514A MX344809B (es) 2005-05-13 2006-04-21 Terapia adyuvante con herceptin.

Country Status (6)

Country Link
US (5) US8591897B2 (es)
JP (9) JP2006316040A (es)
AR (4) AR054254A1 (es)
BR (1) BRPI0601736A (es)
CA (2) CA2790058C (es)
MX (1) MX344809B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2003534292A (ja) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
MX2007000723A (es) 2004-07-22 2007-03-12 Genentch Inc Composicion de anticuerpos her2.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
AU2007243132B2 (en) 2006-01-20 2012-09-13 Genentech, Inc. Anti-EphrinB2 antibodies and methods using same
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
JP2010516741A (ja) * 2007-01-29 2010-05-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ モルホリニルアントラサイクリンおよび抗体を含む抗腫瘍の組み合わせ
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech Inc Predição de resposta a um inibidor de her
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2715319A1 (en) 2008-03-14 2009-09-17 Genentech, Inc. Genetic variations associated with drug resistance
TWI527593B (zh) * 2008-03-18 2016-04-01 建南德克公司 抗ｈｅｒ２抗體-藥物結合物及化療劑之組合及使用方法
WO2009131673A1 (en) * 2008-04-25 2009-10-29 Ludwig Institute For Cancer Research Ltd. Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CN102439452B (zh) * 2009-01-15 2015-04-15 美国控股实验室公司 通过测量her-2表达确定患者应答的方法
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
MX340017B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101801667B1 (ko) 2010-02-04 2017-11-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX2013006392A (es) * 2010-12-09 2013-12-06 Genentech Inc Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
JP6094220B2 (ja) 2011-08-04 2017-03-15 東レ株式会社 膵臓癌の検出方法
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX348577B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
US9181334B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
DK2740489T3 (en) 2011-08-04 2017-01-16 Toray Industries Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
KR102679155B1 (ko) 2011-10-14 2024-06-28 제넨테크, 인크. Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
CA2865020C (en) 2012-02-21 2021-01-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX357965B (es) 2012-03-30 2018-08-01 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
US9416193B2 (en) 2012-03-30 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
CA2879304C (en) 2012-07-19 2020-07-14 Toray Industries, Inc. Method for detecting cancer
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
KR20200085942A (ko) 2013-04-16 2020-07-15 제넨테크, 인크. 페르투주맙 변이체 및 그의 평가
DK3031826T3 (en) 2013-08-09 2018-12-17 Toray Industries Pharmaceutical composition for the treatment and / or prevention of cancer
DK3466976T3 (da) * 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
SG10201809411PA (en) 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3302551B1 (en) 2015-05-30 2024-06-26 F. Hoffmann-La Roche AG Methods of treating her2-positive previously untreated metastatic breast cancer
RS58823B1 (sr) 2015-07-07 2019-07-31 Hoffmann La Roche Kombinovana terapija konjugatom anti-her2 antitelo-lek i bcl-2 inhibitorom
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3493790A4 (en) * 2016-08-02 2020-03-25 Curirx Inc. LIPOSOME PREPARATION METHODS
US11110108B2 (en) * 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
HRP20240069T1 (hr) 2017-03-02 2024-03-29 Genentech, Inc. Adjuvantno liječenje her2-pozitivnog raka dojke
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
CN111278894A (zh) 2017-07-06 2020-06-12 学校法人京都药科大学 肾脏靶向药物递送载体
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN109739435B (zh) * 2018-12-03 2023-10-13 中科恒运股份有限公司 文件存储和更新方法及装置
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
TW202308701A (zh) 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
CA3223304A1 (en) 2021-06-17 2022-12-22 Minghui Pharmaceutical (Hangzhou) Limited Antitumor compound and its application
US20230295348A1 (en) 2022-01-24 2023-09-21 Novimmune Sa Composition and methods for the selective activation of cytokine signaling pathways

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ATE155813T1 (de) 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ES2166352T3 (es) 1989-08-04 2002-04-16 Schering Ag Dominio externo de c-erbb-2:gp75.
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
EP0656367A1 (en) 1991-08-22 1995-06-07 Becton, Dickinson and Company Method and composition for cancer therapy and for prognosticating responses to cancer theraphy
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
AU5355594A (en) 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
US6733752B1 (en) * 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
IL138034A0 (en) 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
SE512710C2 (sv) 1998-07-08 2000-05-02 Ericsson Telefon Ab L M Kapsel för högeffekttransistorchip för höga frekvenser innefattande en elektriskt och termiskt ledande fläns
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
ATE425749T1 (de) 1999-01-27 2009-04-15 Cornell Res Foundation Inc Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
AU782325B2 (en) * 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
JP3485252B2 (ja) 1999-06-16 2004-01-13 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
HU230586B1 (hu) * 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
KR20090024308A (ko) * 1999-08-27 2009-03-06 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2001254672A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6767541B2 (en) 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1275398A4 (en) 2000-04-06 2004-09-01 Kyowa Hakko Kogyo Kk DIAGNOSTICS AND REMEDIES AGAINST RHUMATOID POLYARTHRITIS
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2003534292A (ja) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
KR20100101709A (ko) 2000-12-01 2010-09-17 리스판스 지네틱스, 인크. 표피 성장 인자 수용체 및 ｈｅｒ2-ｎｅｕ 유전자 발현 및 이들 수준과 생존율의 상관성을 측정하는 방법
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
WO2002045653A2 (en) 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002087619A1 (fr) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
US20030068318A1 (en) 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer
US20030175845A1 (en) 2002-03-13 2003-09-18 Kalbag Suresh M. Use of sulfitolysis in high performance peptide mapping
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ITTO20020340A1 (it) 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US20030202973A1 (en) 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
CN1652845A (zh) 2002-05-17 2005-08-10 安万特医药股份有限公司 多西他赛/阿霉素/环磷酰胺在辅助治疗乳腺癌和卵巢癌中的用途
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
US20040013297A1 (en) 2002-07-18 2004-01-22 Roger Lo Method for performing color gamut compression
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
KR101441358B1 (ko) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação

Also Published As

Publication number Publication date
JP2006316040A (ja) 2006-11-24
CA2790058A1 (en) 2006-11-13
US20120003217A1 (en) 2012-01-05
JP2022093642A (ja) 2022-06-23
JP6133668B2 (ja) 2017-05-24
US8597654B2 (en) 2013-12-03
JP2020094061A (ja) 2020-06-18
JP2019011374A (ja) 2019-01-24
AR108615A2 (es) 2018-09-12
US20140086940A1 (en) 2014-03-27
AR054254A1 (es) 2007-06-13
AR088110A2 (es) 2014-05-07
US20060275305A1 (en) 2006-12-07
JP2017132805A (ja) 2017-08-03
JP2015187168A (ja) 2015-10-29
US20200155701A1 (en) 2020-05-21
AR109246A2 (es) 2018-11-14
BRPI0601736A (pt) 2007-05-15
US8591897B2 (en) 2013-11-26
CA2540547C (en) 2016-08-16
US20180236093A1 (en) 2018-08-23
CA2540547A1 (en) 2006-11-13
CA2790058C (en) 2019-01-15
JP2013144718A (ja) 2013-07-25
JP2013163694A (ja) 2013-08-22
JP2017132806A (ja) 2017-08-03

Similar Documents

Publication Publication Date Title
MX344809B (es) Terapia adyuvante con herceptin.
IL258880A (en) Compounds of diarylhydantoin
HK1102757A1 (en) Therapy of platinum-resistant cancer
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
EP1613308A4 (en) CANCER TREATMENT METHODS
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
MX2007005988A (es) Procedimiento sintetico para compuestos de eter aminociclohexilico.
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
WO2004110245A3 (en) Combination therapy for cancer treatment
IL189376A0 (en) Combinations comprising dmxaa for the treatment of cancer
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1615897A4 (en) PYRIMIDINONE COMPOUNDS AS CALCILYTICA
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
WO2003079977A3 (en) Novel compositions and methods in cancer associated with altered expression of mcm3ap
GB0517386D0 (en) Combinations for the treatment of cancer
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer